Erratum: mTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress (Proceedings of the National Academy of Sciences of the United States of America (2014)111 (E2817-E2826) DOI: 10.1073/pnas.1402352111);MTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 27, 2014, Pages E6826-

  Grahammer, Florian ^a   Haenisch, Nora ^b   Steinhardt, Frederic ^a   Sander, Lukas ^a   Roerden, Malte ^b   Arnold, Frederic ^a   Cordts, Tomke ^a   Wanner, Nicola ^a,c   Reichardt, Wilfried ^a   Kerjaschki, Dontscho ^d   Ruegg, Markus A ^e   Hall, Michael N ^e   Moulin, Pierre ^f   Busch, Hauke ^c,g   Boerries, Melanie ^c,g   Walz, Gerd ^a   Artunc, Ferruh ^b   Huber, Tobias B ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF BASEL   (Switzerland)

^f NOVARTIS PHARMA AG   (Switzerland)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Acute kidney injury; Mitochondrial biogenesis; mTOR; Tubular transport; Urinary concentration mechanism

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOGENESIS; CELL LOSS; CELL METABOLISM; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; EMBRYO; ENERGY METABOLISM; ENERGY RESOURCE; EPITHELIUM CELL; GENE EXPRESSION PROFILING; HOMEOSTASIS; KIDNEY CONCENTRATING CAPACITY; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TUBULE CELL; KIDNEY TUBULE EPITHELIUM; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; TRANSCYTOSIS;

ACUTE KIDNEY INJURY; MITOCHONDRIAL BIOGENESIS; MTOR; TUBULAR TRANSPORT; URINARY CONCENTRATION MECHANISM;

ANIMALS; BLOTTING, WESTERN; HOMEOSTASIS; ISCHEMIA; KIDNEY TUBULES; MAGNETIC RESONANCE IMAGING; MICE; MULTIPROTEIN COMPLEXES; POLYURIA; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 84903957218     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1522405112     Document Type: Erratum

References (44)

1. Greger R (2000) Physiology of renal sodium transport. Am J Med Sci 319(1):51-62.
2. Hoorn EJ, Nelson JH, McCormick JA, Ellison DH (2011) The WNK kinase network regulating sodium, potassium, and blood pressure. J Am Soc Nephrol 22(4):605-614.
3. Mercier-Zuber A, O'Shaughnessy KM (2011) Role of SPAK and OSR1 signalling in the regulation of NaCl cotransporters. Curr Opin Nephrol Hypertens 20(5):534-540.
4. Mandel LJ, Balaban RS (1981) Stoichiometry and coupling of active transport to oxidative metabolism in epithelial tissues. Am J Physiol 240(5):F357-F371. (Pubitemid 11112946)
5. Mandel LJ (1986) Primary active sodium transport, oxygen consumption, and ATP: Coupling and regulation. Kidney Int 29(1):3-9.
6. Soltoff SP (1986) ATP and the regulation of renal cell function. Annu Rev Physiol 48:9-31.
7. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124(3):471-484. (Pubitemid 43199434)
8. Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253(5022):905-909. (Pubitemid 21917235)
9. Sarbassov DD, et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14(14):1296-1302.
10. Jacinto E, et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6(11):1122-1128. (Pubitemid 39468014)
11. Kim DH, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110(2):163-175.
12. Hara K, et al. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110(2):177-189. (Pubitemid 34876546)
13. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274-293.
14. Peterson TR, et al. (2011) mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146(3):408-420.
15. Golbaekdal K, Nielsen CB, Djurhuus JC, Pedersen EB (1994) Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin in pigs. Transplantation 58(11):1153-1157.
16. Haller M, et al. (2012) Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. PLoS ONE 7(7):e39229.
17. Morales JM, et al. (2003) Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation. Transplant Proc 35(3, Suppl):154S-156S. (Pubitemid 36547937)
18. Morales JM, et al.; Sirolimus European Renal Transplant Study Group (2002) Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2(5):436-442.
19. Kempe DS, et al. (2010) Rapamycin-induced phosphaturia. Nephrol Dial Transplant 25(9):2938-2944.
20. Smith KD, et al. (2003) Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 14(4):1037-1045. (Pubitemid 36359286)
21. Lieberthal W, Fuhro R, Andry C, Patel V, Levine JS (2006) Rapamycin delays but does not prevent recovery from acute renal failure: Role of acquired tubular resistance. Transplantation 82(1):17-22. (Pubitemid 44296972)
22. Bissler JJ, et al. (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381(9869):817-824.
23. Hudes G, et al.; Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271-2281. (Pubitemid 46849157)
24. Baselga J, et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520-529.
25. Shao X, Somlo S, Igarashi P (2002) Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J Am Soc Nephrol 13(7):1837-1846. (Pubitemid 34700608)
26. Luo W, Friedman MS, Shedden K, Hankenson KD, Woolf PJ (2009) GAGE: Generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics 10:161.
27. Cunningham JT, et al. (2007) mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450(7170):736-740. (Pubitemid 350207689)
28. Takahashi N, et al. (2000) Uncompensated polyuria in a mouse model of Bartter's syndrome. Proc Natl Acad Sci USA 97(10):5434-5439. (Pubitemid 30313736)
29. Devuyst O (2012) Physiopathology and diagnosis of nephrogenic diabetes insipidus. Ann Endocrinol (Paris) 73(2):128-129.
30. Schieke SM, et al. (2006) The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem 281(37):27643-27652. (Pubitemid 44401789)
31. Guertin DA, et al. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11(6):859-871. (Pubitemid 44804279)
32. Canaud G, et al. (2013) AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med 19(10):1288-1296.
33. Gödel M, et al. (2011) Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 121(6):2197-2209.
34. Brooks C, Wei Q, Cho SG, Dong Z (2009) Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 119(5):1275-1285.
35. Traykova-Brauch M, et al. (2008) An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med 14(9):979-984.
36. Kezic A, Thaiss F, Becker JU, Tsui TY, Bajcetic M (2013) Effects of everolimus on oxidative stress in kidney model of ischemia/reperfusion injury. Am J Nephrol 37(4):291-301.
37. Committee on Care and Use of Laboratory Animals (1985) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.
38. Bentzinger CF, et al. (2008) Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab 8(5):411-424.
39. Eremina V, et al. (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358(11):1129-1136. (Pubitemid 351398487)
40. Artunc F, et al. (2009) Responses to diuretic treatment in gene-targeted mice lacking serum- and glucocorticoid-inducible kinase 1. Kidney Blood Press Res 32(2):119-127.
41. Piccolo SR, et al. (2012) A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics 100(6):337-344.
42. Dai M, et al. (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33(20):e175.
43. Avner ED, Villee DB, Schneeberger EE, Grupe WE (1983) An organ culture model for the study of metanephric development. J Urol 129(3):660-664. (Pubitemid 13128811)
44. Gao X, et al. (2005) Angioblast-mesenchyme induction of early kidney development is mediated by Wt1 and Vegfa. Development 132(24):5437-5449. (Pubitemid 43125871)